Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells.

Proteomics - 1 Aug 2023

Aguilar-Valdés Alain, González-Vela Francisco, Sánchez-Vidal Hilda, Martínez-Aguilar Juan

Abstract excerpt

Pancreatic cancer is one of the most lethal cancer types and is becoming a leading cause of cancer-related deaths. The limited benefit offered by chemotherapy agents has propelled the search for alternative approaches that target specific molecular drivers of cancer growth and progression. Mutant KRas and effector pathways Raf/MEK/ERK and PI3K/Akt are key players in pancreatic cancer; however, preclinical studies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to Protein Kinase Inhibitors

Share to Proteomics

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37140101
DOI: 10.1002/pmic.202300041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells.PMID 37140101Read ↗

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistanceSemantic proximity Read ↗

Opportunities and Resistance to Signal-targeted Therapies in Pancreatic Cancer: What Can We Learn from Proteomic Studies?Semantic proximity Read ↗

Opportunities and Resistance to Signal-Targeted Therapies in Pancreatic Cancer: What Can we Learn from Proteomic Studies?Semantic proximity Read ↗

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular PlasticitySemantic proximity Read ↗

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity Read ↗

Emerging role of the KRAS-PDK1 axis in pancreatic cancer.Semantic proximity Read ↗

Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?Semantic proximity Read ↗

p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.Semantic proximity Read ↗

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.Semantic proximity Read ↗

Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.Semantic proximity Read ↗

Proteomics in pancreatic cancer researchSemantic proximity Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.